Please try another search
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Name | Age | Since | Title |
---|---|---|---|
Neil Harris Cohen | 58 | 2020 | Independent Director |
Alan Charles Moses | 74 | 2021 | Independent Director |
Arun J. Sanyal | - | - | Member of Scientific Advisory Board |
Nissim Darvish | 59 | 2021 | Independent Chairman |
Massimo Pinzani | - | - | Member of Scientific Advisory Board |
Claude Nicaise | 70 | 2021 | Independent Director |
Adi Mor George | 41 | 2011 | Co-Founder, Chief Scientific Officer, CEO & Executive Director |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Jill M. Quigley | 47 | 2022 | Independent Director |
Jacob George | - | - | Member of Scientific Advisory Board |
Dinesh Khanna | - | - | Member of Scientific Advisory Board |
Francesco Del Galdo | - | - | Member of Scientific Advisory Board |
Marco Matucci-Cerinic | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review